🇺🇸 FDA
Patent

US 11639355

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

granted A61PA61P31/04A61P31/12

Quick answer

US patent 11639355 (Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors) held by Medshine Discovery Inc. expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P31/04, A61P31/12, A61P35/00, A61P35/02